Bristol-Myers Squibb Company (BMY) Revenue, Earnings & Financial Statements
$63.04NYSE: BMYMarket Cap $128.86B
Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)
Bristol-Myers Squibb Company most recently reported annual revenue of $48.2B, net profit of $7.1B. Revenue grew at an average annual rate of 2.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Bristol-Myers Squibb Company: Revenue rose from $19.4B in 2016 to $48.2B in 2025, a change of +148.1% over 9 years; net profit was positive in 8 of 10 reported years; operating margin moved from 23.0% to 28.5%, a shift of +5.5 percentage points; the most recent year shows net profit of $7.1B.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$19.4B
$20.8B
$22.6B
$26.1B
$42.5B
$46.4B
$46.2B
$45.0B
$48.3B
$48.2B
Operating Expenses
$15.0B
$17.3B
$17.4B
$20.2B
$40.3B
$37.8B
$37.1B
$36.8B
$42.4B
$34.5B
Operating Profit
$4.5B
$3.4B
$5.1B
$5.9B
$2.2B
$8.5B
$9.1B
$8.2B
$5.9B
$13.7B
Operating Margin
23.0%
16.6%
22.7%
22.6%
5.1%
18.4%
19.7%
18.2%
12.2%
28.5%
Other Income
$1.4B
$1.7B
$854.0M
−$938.0M
−$9.0B
−$439.0M
−$1.4B
$245.0M
−$14.3B
−$4.4B
Interest
$167.0M
$196.0M
$183.0M
$656.0M
$1.4B
$1.3B
$1.2B
$1.2B
$1.9B
$1.9B
Depreciation
$382.0M
$789.0M
$637.0M
$1.7B
$10.4B
$10.7B
$10.3B
$9.8B
$9.6B
$4.0B
Profit Before Tax
$5.9B
$5.1B
$6.0B
$5.0B
−$6.9B
$8.1B
$7.7B
$8.4B
−$8.4B
$9.3B
Tax rate (%)
23.8%
81.0%
17.1%
30.4%
-30.9%
13.4%
17.7%
4.7%
-6.6%
24.4%
Net Profit
$4.5B
$1.0B
$4.9B
$3.4B
−$9.0B
$7.0B
$6.3B
$8.0B
−$8.9B
$7.1B
EPS
$2.65
$0.61
$3.03
$2.01
−$3.98
$3.12
$2.95
$3.86
−$4.41
$3.45
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$11.0B
$11.5B
$11.9B
$12.2B
$11.9B
$12.3B
$11.2B
$12.3B
$12.2B
$12.5B
$11.5B
$13.0B
Operating Expenses
$8.9B
$9.5B
$10.3B
$9.6B
$9.6B
$9.8B
$7.7B
$8.5B
$8.6B
$9.7B
$8.1B
$8.9B
Operating Profit
$2.1B
$2.0B
$1.5B
$2.6B
$2.3B
$2.5B
$3.5B
$3.8B
$3.6B
$2.8B
$3.4B
$4.1B
Operating Margin
19.2%
17.0%
12.9%
21.2%
19.2%
20.5%
31.2%
30.8%
29.8%
22.5%
29.3%
31.5%
Interest
$280.0M
$316.0M
$425.0M
$521.0M
$505.0M
$496.0M
$494.0M
$485.0M
$480.0M
$432.0M
$411.0M
$407.0M
Profit Before Tax
$2.1B
$1.7B
−$11.5B
$1.3B
$1.7B
$175.0M
$3.0B
$1.8B
$3.1B
$1.5B
$3.2B
$4.1B
Tax rate (%)
9.5%
-5.3%
-3.4%
-30.9%
27.5%
56.6%
17.1%
25.9%
29.5%
26.1%
17.3%
18.8%
Net Profit
$1.9B
$1.8B
−$11.9B
$1.7B
$1.2B
$72.0M
$2.5B
$1.3B
$2.2B
$1.1B
$2.7B
$3.3B
EPS
$0.93
$0.87
−$5.89
$0.83
$0.60
$0.04
$1.20
$0.64
$1.08
$0.53
$1.31
$1.62
Over the 10 years reported for Bristol-Myers Squibb Company, borrowings increased from $6.7B in 2016 to $47.1B in 2025, cash stood at $10.2B in the latest year, shareholders' equity was $292.0M, current assets covered current liabilities 1.26 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$33.7B
$33.6B
$35.0B
$129.9B
$118.5B
$109.3B
$96.8B
$95.2B
$92.6B
$90.0B
Current Assets
$13.7B
$14.9B
$17.7B
$29.4B
$30.2B
$33.3B
$27.3B
$31.8B
$29.8B
$29.4B
Cash
$4.2B
$5.4B
$6.9B
$12.3B
$14.5B
$14.0B
$9.1B
$11.5B
$10.3B
$10.2B
Inventory
$1.2B
$1.2B
$1.2B
$4.3B
$2.1B
$2.1B
$2.3B
$2.7B
$2.6B
$2.7B
Receivables
$5.5B
$6.3B
$5.7B
$7.7B
$10.6B
$12.5B
$13.9B
$15.3B
$14.4B
$14.5B
Fixed Assets
$5.0B
$5.0B
$5.0B
$7.0B
$6.7B
$7.0B
$7.5B
$8.0B
$8.4B
$9.1B
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$4.8B
$3.9B
$3.6B
$7.2B
$6.4B
$6.0B
$2.3B
$3.3B
$3.0B
$3.0B
Other Assets
$6.9B
$6.9B
$6.5B
$22.5B
$20.5B
$20.5B
$21.1B
$21.2B
$21.7B
$21.8B
Total Liabilities
$17.4B
$21.7B
$20.9B
$78.2B
$80.6B
$73.3B
$65.7B
$65.7B
$76.2B
$71.5B
Current Liabilities
$8.8B
$9.6B
$10.7B
$18.3B
$19.1B
$21.9B
$21.9B
$22.3B
$23.8B
$23.4B
Borrowings
$6.7B
$8.0B
$7.3B
$47.5B
$51.7B
$45.6B
$40.7B
$41.5B
$51.2B
$47.1B
Other Liabilities
$10.7B
$13.7B
$13.5B
$30.7B
$28.9B
$27.7B
$25.0B
$24.2B
$25.0B
$24.4B
Equity
$221.0M
$221.0M
$221.0M
$292.0M
$292.0M
$292.0M
$292.0M
$292.0M
$292.0M
$292.0M
Reserves
$16.2B
$11.7B
$14.0B
$51.6B
$37.8B
$35.9B
$31.1B
$29.4B
$16.3B
$18.5B
For Bristol-Myers Squibb Company, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $12.8B; free cash flow was positive in 10 of 10 years.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$3.1B
$5.3B
$7.1B
$8.2B
$14.1B
$16.2B
$13.1B
$13.9B
$15.2B
$14.2B
Investing Cash Flow
$265.0M
−$1.1B
−$3.0B
−$10.7B
−$11.6B
−$1.5B
−$2.2B
−$3.5B
−$22.6B
−$5.4B
Financing Cash Flow
−$216.0M
−$2.5B
−$374.0M
−$7.4B
−$1.0B
−$5.6B
−$7.0B
−$5.1B
$0
$0
Net Cash Flow
$1.9B
$1.2B
$1.5B
$5.9B
$2.2B
−$657.0M
−$5.0B
$2.2B
−$1.2B
−$137.0M
Free Cash Flow
$1.8B
$4.2B
$6.1B
$7.4B
$13.3B
$15.2B
$11.9B
$12.7B
$13.9B
$12.8B
Valuation & Return Ratios
Metric
Value
PEG Ratio
4.88
EV / EBITDA
9.24
FCF Yield
10.11%
Quick Ratio
1.14
Interest Coverage
7.26
Return 1Y
36.24%
Return 3Y
44.62%
Return 5Y
30.20%
Bristol-Myers Squibb Company (BMY) financials — frequently asked questions
What is Bristol-Myers Squibb Company's annual revenue?
Bristol-Myers Squibb Company (BMY) reported annual revenue of $48.2B in its most recent fiscal year.
What is Bristol-Myers Squibb Company's net profit?
Bristol-Myers Squibb Company (BMY) reported net profit of $7.1B in its most recent fiscal year.
What is BMY EV/EBITDA?
Bristol-Myers Squibb Company's enterprise value to EBITDA (EV/EBITDA) ratio is 9.24.
Revenue and earnings of other Drug Manufacturers - General stocks